MET Immunohistochemistry Should Be Avoided in Selecting Non-small-cell Lung Cancers Requiring MET Exon 14 Skipping Mutation Analysis

被引：5
|
作者：
Lambros, Laetitia [1 ]
Uguen, Arnaud [1 ,2 ]
机构：
[1] CHRU Brest, Dept Pathol, Brest, France
[2] INSERM, U1053 BaRITOn, Bordeaux, France
来源：
CLINICAL LUNG CANCER | 2019年 / 20卷 / 03期
关键词：
D O I：
10.1016/j.cllc.2018.12.002
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E418 / E420
页数：3
相关论文
共 50 条
  • [1] Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
    Paik, Paul K.
    Felip, Enriqueta
    Veillon, Remi
    Sakai, Hiroshi
    Cortot, Alexis B.
    Garassino, Marina C.
    Mazieres, Julien
    Viteri, Santiago
    Senellart, Helene
    Van Meerbeeck, Jan
    Raskin, Jo
    Reinmuth, Niels
    Conte, Pierfranco
    Kowalski, Dariusz
    Cho, Byoung Chul
    Patel, Jyoti D.
    Horn, Leora
    Griesinger, Frank
    Han, Ji-Youn
    Kim, Young-Chul
    Chang, Gee-Chen
    Tsai, Chen-Liang
    Yang, James C. -H.
    Chen, Yuh-Min
    Smit, Egbert F.
    van der Wekken, Anthonie J.
    Kato, Terufumi
    Juraeva, Dilafruz
    Stroh, Christopher
    Bruns, Rolf
    Straub, Josef
    Johne, Andreas
    Scheele, Juergen
    Heymach, John V.
    Le, Xiuning
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (10): : 931 - 943
  • [2] Absence of cross-toxicity between MET inhibitors in a non-small-cell lung cancer with a MET exon 14 skipping mutation
    Vanderick, Ariane
    Colinet, Benoit
    ACTA CLINICA BELGICA, 2024, 79 (02) : 148 - 151
  • [3] Case series of MET exon 14 skipping mutation-positive non-small-cell lung cancers with response to crizotinib and cabozantinib
    Wang, Samantha X. Y.
    Zhang, Bing M.
    Wakelee, Heather A.
    Koontz, Michael Z.
    Pan, MingGui
    Diehn, Maximilian
    Kunder, Christian A.
    Neal, Joel W.
    ANTI-CANCER DRUGS, 2019, 30 (05) : 537 - 541
  • [4] Tepotinib for advanced non-small-cell lung cancer with MET exon 14 skipping mutations
    Blaszkowska, M.
    Specht-Szwoch, Z.
    Dziadziuszko, R.
    ESMO OPEN, 2022, 7 (02)
  • [5] Molecular Diagnostic Assays and Clinicopathologic Implications of MET Exon 14 Skipping Mutation in Non-small-cell Lung Cancer
    Kim, Eun Kyung
    Kim, Kyung A.
    Lee, Chang Young
    Kim, Sangwoo
    Chang, Sunhee
    Cho, Byoung Chul
    Shim, Hyo Sup
    CLINICAL LUNG CANCER, 2019, 20 (01) : E123 - E132
  • [6] MET Exon 14 Skipping in Non-Small Cell Lung Cancer
    Heist, Rebecca S.
    Shim, Hyo Sup
    Gingipally, Shalini
    Mino-Kenudson, Mari
    Le, Long
    Gainor, Justin F.
    Zheng, Zongli
    Aryee, Martin
    Xia, Junfeng
    Jia, Peilin
    Jin, Hailing
    Zhao, Zhongming
    Pao, Gwilliam
    Engelman, Jeffrey A.
    Iafrate, A. John
    ONCOLOGIST, 2016, 21 (04): : 481 - 486
  • [7] Non-small-cell lung cancer: how to manage MET exon 14 skipping mutant disease
    Blaquier, Juan Bautista
    Recondo, Gonzalo
    DRUGS IN CONTEXT, 2022, 11
  • [8] Clinicopathologic and Imaging Features of Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
    Digumarthy, Subba R.
    Mendoza, Dexter P.
    Zhang, Eric W.
    Lennerz, Jochen K.
    Heist, Rebecca S.
    CANCERS, 2019, 11 (12)
  • [9] Case Series of MET Exon 14 Skipping Mutation-Positive Non-Small Cell Lung Cancers and Response to Crizotinib
    Wang, Samantha X.
    Zhang, Bing M.
    Wakelee, Heather
    Diehn, Maximilian
    Kunder, Christian A.
    Neal, Joel W.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (11) : S312 - S313
  • [10] Case Series of MET Exon 14 Skipping Mutation-positive Non-Small Cell Lung Cancers and Response to Crizotinib
    Wang, S. X.
    Zhang, B.
    Wakelee, H. A.
    Diehn, M.
    Kunder, C.
    Neal, J. W.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 98 (01): : 239 - 239
12345